Article Received-Palestine-P

COVID 19 and Remdesivir As suggested treatment

Akram Atalla, Saeb Aliwaini, Sana al tawil, Sahar Abu Asaker, Ebaa Al FarraandAlaa Al Rabey

Review article

 University of Palestine, Medicine and health Science College, Pharmacy and Biotechnology Department
a.atallah@up.edu.ps

Abstract

The 2019-nCoV has been identified as the cause of an outbreak of respiratory illness in Wuhan, Hubei Province, China beginning in December 2019. This epidemic had spread to 19 countries with 11,791 confirmed cases, including 213 deaths, as of January 31, 2020. The World Health Organization declared it as a Public Health Emergency of International Concern. This study analyzed and discussed 60 research articles for a better understanding of the epidemiology, pathogenesis, clinical manifestation, diagnosis and suggested antiviral drug Remdesivir for the treatment of COVID19. Studies thus far have shown origination in connection to a seafood market in Wuhan, but specific animal association has not been confirmed. The reported symptoms include fever, cough, fatigue, pneumonia, headache, diarrhea, hemoptysis, and dyspnea. The virus can infect humans by interacting with them ACE2 receptors that distributed widely in nasal mucosa, bronchus, lung, heart, esophagus, kidney, stomach, bladder, and ileum, and these human organs are all vulnerable to SARS-CoV 2.To date, no specific antiviral treatment is proven effective; hence, infected people primarily rely on symptomatic treatment and supportive care. However, the use of some antivirals such as Remdesivir has been shown to help speed up the recovery process and bypass the dangerous stage.Although these studies had relevance to control a public emergency, more research need to be conducted to provide valid and reliable ways to manage this kind of public health emergency in both short- and long- term.

Key words: Wuhan – COVID 19 – pandemic – SARS –Remdesivir